Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

Author:

Hoves Sabine1,Ooi Chia-Huey12ORCID,Wolter Carsten1,Sade Hadassah1,Bissinger Stefan1ORCID,Schmittnaegel Martina3ORCID,Ast Oliver4ORCID,Giusti Anna M.4,Wartha Katharina1ORCID,Runza Valeria1ORCID,Xu Wei4,Kienast Yvonne1,Cannarile Michael A.1,Levitsky Hyam4ORCID,Romagnoli Solange1ORCID,De Palma Michele3ORCID,Rüttinger Dominik1,Ries Carola H.1ORCID

Affiliation:

1. Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

2. Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

3. Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

4. Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Abstract

Depletion of immunosuppressive tumor-associated macrophages (TAMs) or reprogramming toward a proinflammatory activation state represent different strategies to therapeutically target this abundant myeloid population. In this study, we report that inhibition of colony-stimulating factor-1 receptor (CSF-1R) signaling sensitizes TAMs to profound and rapid reprogramming in the presence of a CD40 agonist before their depletion. Despite the short-lived nature of macrophage hyperactivation, combined CSF-1R+CD40 stimulation of macrophages is sufficient to create a proinflammatory tumor milieu that reinvigorates an effective T cell response in transplanted tumors that are either responsive or insensitive to immune checkpoint blockade. The central role of macrophages in regulating preexisting immunity is substantiated by depletion experiments, transcriptome analysis of ex vivo sorted TAMs, and gene expression profiling of whole tumor lysates at an early treatment time point. This approach enabled the identification of specific combination-induced changes among the pleiotropic activation spectrum of the CD40 agonist. In patients, CD40 expression on human TAMs was detected in mesothelioma and colorectal adenocarcinoma.

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3